This Cancer Screening Company Has A Better 5-Year Return Than Pfizer, Johnson & Johnson And Gilead
Small-cap stocks have a history of outperforming large-cap names as they have the potential for rapid growth and have event-driven moves for share prices.
A company focused on cancer screening and diagnostic tests has outperformed some of the largest healthcare companies over the last five years and went from small-cap to a market cap of more than $18 billion.